CORRECTION — Gritstone Reports First Quarter 2022 Financial Results and Provides Business Update

Gritstone bio, Inc — Clinical programs continue progressing, with multiple Phase 2 data catalysts from neoantigen oncology vaccine programs and additional human data evaluating self-amplifying mRNA (samRNA) vaccines against viruses expected over the next 18 months — — Recent presentations reinforce expertise in vaccine design and delivery and potential of […]

Subscribe US Now